Matches in SemOpenAlex for { <https://semopenalex.org/work/W1551444218> ?p ?o ?g. }
- W1551444218 abstract "Background Mitochondrial respiratory chain disorders are the most prevalent group of inherited neurometabolic diseases. They present with central and peripheral neurological features usually in association with other organ involvement including the eye, the heart, the liver, and kidneys, diabetes mellitus and sensorineural deafness. Current treatment is largely supportive and the disorders progress relentlessly causing significant morbidity and premature death. Vitamin supplements, pharmacological agents and exercise therapy have been used in isolated cases and small clinical trials, but the efficacy of these interventions is unclear. The first review was carried out in 2003, and identified six clinical trials. This major update was carried out to identify new studies and grade the original studies for potential bias in accordance with revised Cochrane Collaboration guidelines. Objectives To determine whether there is objective evidence to support the use of current treatments for mitochondrial disease. Search methods We searched the Cochrane Neuromuscular Disease Group Specialized Register (4 July 2011), CENTRAL (2011, Issue 2, MEDLINE (1966 to July 2011), and EMBASE (January 1980 to July 2011), and contacted experts in the field. Selection criteria We included randomised controlled trials (including cross‐over studies). Two of the authors independently selected abstracts for further detailed review. Further review was performed independently by all five authors to decide which trials fit the inclusion criteria and graded risk of bias. Participants included males and females of any age with a confirmed diagnosis of mitochondrial disease based upon muscle histochemistry, respiratory chain complex analysis of tissues or cell lines or DNA studies. Interventions included any pharmacological agent, dietary modification, nutritional supplement, exercise therapy or other treatment. The review authors excluded studies at high risk of bias in any category. The primary outcome measures included an change in muscle strength and/or endurance, or neurological clinical features. Secondary outcome measures included quality of life assessments, biochemical markers of disease and negative outcomes. Data collection and analysis Two of the authors (GP and PFC) independently identified studies for further evaluation from all abstracts within the search period. For those studies identified for further review, all five authors then independently assessed which studies met the entry criteria. For the included studies, we extracted details of the number of randomised participants, treatment, study design, study category, allocation concealment and other risk of bias criteria, and participant characteristics. Analysis was based on intention‐to‐treat data. We planned to use meta‐analysis, but this did not prove necessary. Main results The authors reviewed 1335 abstracts, and from these identified 21 potentially eligible abstracts. Upon detailed review, 12 studies fulfilled the entry criteria. Of these, eight were new studies that had been published since the previous version of this review. Two studies which were included in the previous version of this review were excluded because of potential for bias. The comparability of the included studies is extremely low because of differences in the specific diseases studied, differences in the therapeutic agents used, dosage, study design, and outcomes. The methodological quality of included studies was generally high, although risk of bias was unclear in random sequence generation and allocation concealment for most studies. Otherwise, the risk of bias was low for most studies in the other categories. Serious adverse events were uncommon, except for peripheral nerve toxicity in a long‐term trial of dichloroacetate (DCA) in adults. One trial studied high‐dose coenzyme Q10 without clinically meaningful improvement (although there were multiple biochemical, physiologic, and neuroimaging outcomes, in 30 participants). Three trials used creatine monohydrate alone, with one reporting evidence of improved measures of muscle strength and post‐exercise lactate, but the other two reported no benefit (total of 38 participants). One trial studied the effects of a combination of coenzyme Q10, creatine monohydrate, and lipoic acid and reported a statistically significant improvement in biochemical markers and peak ankle dorsiflexion strength, but overall no clinical improvement in 16 participants. Five trials studied the effects of DCA: three trials in children showed a statistically significant improvement in secondary outcome measures of mitochondrial metabolism (venous lactate in three trials, and magnetic resonance spectroscopy (MRS) in one trial; total of 63 participants). One trial of short‐term DCA in adults demonstrated no clinically relevant improvement (improved venous lactate but no change in physiologic, imaging, or questionnaire findings, in eight participants). One longer‐term DCA trial in adults was terminated prematurely due to peripheral nerve toxicity without clinical benefit (assessments included the GATE score, venous lactate and MRS, in 30 participants). One trial using dimethylglycine showed no significant effect (measurements of venous lactate and oxygen consumption (VO2) in five participants). One trial using a whey‐based supplement showed statistically significant improvement in markers of free radical reducing capacity but no clinical benefit (assessments included the Short Form 36 Health Survey (SF‐36) questionnaire and UK Medical Research Council (MRC) muscle strength, in 13 participants). Authors' conclusions Despite identifying eight new trials there is currently no clear evidence supporting the use of any intervention in mitochondrial disorders. Further research is needed to establish the role of a wide range of therapeutic approaches. We suggest further research should identify novel agents to be tested in homogeneous study populations with clinically relevant primary endpoints." @default.
- W1551444218 created "2016-06-24" @default.
- W1551444218 creator A5013583757 @default.
- W1551444218 creator A5047836141 @default.
- W1551444218 creator A5050697713 @default.
- W1551444218 creator A5054502094 @default.
- W1551444218 creator A5068279800 @default.
- W1551444218 date "2012-04-18" @default.
- W1551444218 modified "2023-10-16" @default.
- W1551444218 title "Treatment for mitochondrial disorders" @default.
- W1551444218 cites W1487623199 @default.
- W1551444218 cites W1535907462 @default.
- W1551444218 cites W1551996591 @default.
- W1551444218 cites W1576093526 @default.
- W1551444218 cites W1582167793 @default.
- W1551444218 cites W1603646385 @default.
- W1551444218 cites W1665535554 @default.
- W1551444218 cites W176753646 @default.
- W1551444218 cites W1964077809 @default.
- W1551444218 cites W1965634593 @default.
- W1551444218 cites W1966508677 @default.
- W1551444218 cites W1966691625 @default.
- W1551444218 cites W1972922254 @default.
- W1551444218 cites W1977362203 @default.
- W1551444218 cites W1978639395 @default.
- W1551444218 cites W1979438859 @default.
- W1551444218 cites W1979516784 @default.
- W1551444218 cites W1982348732 @default.
- W1551444218 cites W1984247439 @default.
- W1551444218 cites W1985665857 @default.
- W1551444218 cites W1991872974 @default.
- W1551444218 cites W1992544893 @default.
- W1551444218 cites W1993103503 @default.
- W1551444218 cites W1993215625 @default.
- W1551444218 cites W1993353735 @default.
- W1551444218 cites W1998107356 @default.
- W1551444218 cites W2001776282 @default.
- W1551444218 cites W2004334615 @default.
- W1551444218 cites W2010476133 @default.
- W1551444218 cites W2010583179 @default.
- W1551444218 cites W2011646422 @default.
- W1551444218 cites W2012965847 @default.
- W1551444218 cites W2013550901 @default.
- W1551444218 cites W2018756502 @default.
- W1551444218 cites W2019271502 @default.
- W1551444218 cites W2029386258 @default.
- W1551444218 cites W2032234589 @default.
- W1551444218 cites W2037717843 @default.
- W1551444218 cites W2037880185 @default.
- W1551444218 cites W2042609760 @default.
- W1551444218 cites W2043823315 @default.
- W1551444218 cites W2044494908 @default.
- W1551444218 cites W2047455456 @default.
- W1551444218 cites W2047973587 @default.
- W1551444218 cites W2052771873 @default.
- W1551444218 cites W2054478746 @default.
- W1551444218 cites W2055758029 @default.
- W1551444218 cites W2057092244 @default.
- W1551444218 cites W2057563504 @default.
- W1551444218 cites W2059794658 @default.
- W1551444218 cites W2060677143 @default.
- W1551444218 cites W2060936796 @default.
- W1551444218 cites W2063874785 @default.
- W1551444218 cites W2072334589 @default.
- W1551444218 cites W2072969519 @default.
- W1551444218 cites W2074544794 @default.
- W1551444218 cites W2077414996 @default.
- W1551444218 cites W2078343464 @default.
- W1551444218 cites W2085080970 @default.
- W1551444218 cites W2085752695 @default.
- W1551444218 cites W2089847769 @default.
- W1551444218 cites W2090716019 @default.
- W1551444218 cites W2090988198 @default.
- W1551444218 cites W2092352962 @default.
- W1551444218 cites W2094521844 @default.
- W1551444218 cites W2095566500 @default.
- W1551444218 cites W2097076310 @default.
- W1551444218 cites W2100704541 @default.
- W1551444218 cites W2107120433 @default.
- W1551444218 cites W2109291482 @default.
- W1551444218 cites W2111001861 @default.
- W1551444218 cites W2115486963 @default.
- W1551444218 cites W2126169273 @default.
- W1551444218 cites W2127742497 @default.
- W1551444218 cites W2130183664 @default.
- W1551444218 cites W2134857359 @default.
- W1551444218 cites W2137286173 @default.
- W1551444218 cites W2140462925 @default.
- W1551444218 cites W2149755406 @default.
- W1551444218 cites W2150280008 @default.
- W1551444218 cites W2152322786 @default.
- W1551444218 cites W2154313346 @default.
- W1551444218 cites W2158229676 @default.
- W1551444218 cites W2170076251 @default.
- W1551444218 cites W2328596111 @default.
- W1551444218 cites W2399389442 @default.
- W1551444218 cites W312070627 @default.
- W1551444218 cites W408505 @default.
- W1551444218 cites W4211080783 @default.
- W1551444218 cites W4229670314 @default.